Placebo Causes Adverse Reaction With Industry, Raises Regulatory Concerns
This article was originally published in The Tan Sheet
Executive Summary
An inert sugar pill marketed as a placebo for ailing children will likely attract regulatory interest from the Federal Trade Commission as well as FDA, according to industry experts
You may also be interested in...
Pediatric CVD Report Slights Nutrition’s Role, Weighs On OTC Statin Chances
An American Academy of Pediatrics report recommending prescribing statin drugs for cardiovascular disease in children could present another roadblock for switching statins to OTC
Pediatric CVD Report Slights Nutrition’s Role, Weighs On OTC Statin Chances
An American Academy of Pediatrics report recommending prescribing statin drugs for cardiovascular disease in children could present another roadblock for switching statins to OTC
Pediatric CVD Report Slights Nutrition’s Role, Weighs On OTC Statin Chances
An American Academy of Pediatrics report recommending prescribing statin drugs for cardiovascular disease in children could present another roadblock for switching statins to OTC